Cantor Fitzgerald Downgrades Cognition Therapeutics (CGTX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts CGTX Hot Sheet
Price: $0.68 --0%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles Duncan downgraded Cognition Therapeutics (NASDAQ: CGTX) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Cognition Therapeutics click here. For more ratings news on Cognition Therapeutics click here.
Shares of Cognition Therapeutics closed at $2.37 yesterday.
You May Also Be Interested In
- Cognition Therapeutics, Inc. (CGTX) Tops Q3 EPS by 3c
- Northland Downgrades ThredUp Inc. (TDUP) to Market Perform, 'Headwinds On Growth & Margins Moves Us To Sideline'
- Freedom Broker Downgrades McDonald's (MCD) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
